Do we still need liver biopsies?

  • C. Flechtenmacher
  • T. Longerich
  • P. Schirmacher
Conference paper
Part of the Falk Symposium book series (FASS, volume 160)


Liver biopsies are obtained as a diagnostic measure to either evaluate diffuse liver diseases or focal liver processes. Since liver biopsy, despite technical improvements, is not without risk for the patient1, its indication has to be made carefully in a proper clinical context. The information obtained following liver biopsy has to have an impact on the therapeutic decision (therapy planning, prognosis assessment)2 and cannot be achieved by an easier, cheaper, or less invasive procedure. Thus the application of liver biopsy is subjected to changes in diagnostic algorithms, therapeutic options, and disease management.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies. J Hepatol. 1986;2:165–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999;45 (Suppl. 4):IV1–11.Google Scholar
  3. 3.
    Crawford AR, Lin XZ, Crawford JM. The normal adult human liver biopsy: a quantitative reference standard. Hepatology. 1998;28:323–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Pradat P, Alberti A, Poynard T et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002;36:973–7.PubMedGoogle Scholar
  5. 5.
    Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–20.PubMedGoogle Scholar
  6. 6.
    Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–17.PubMedCrossRefGoogle Scholar
  7. 7.
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Fernandez-Rodriguez CM, Gutierrez ML, Serrano PL et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci. 2004;49:1971–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Monto A, Patel K, Bostrom A et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology. 2004;39:826–34.PubMedCrossRefGoogle Scholar
  11. 11.
    Walsh MJ, Vanags DM, Clouston AD et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology. 2004;39:1230–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36(Suppl. 1):S47–56.CrossRefGoogle Scholar
  13. 13.
    Alvarez F, Berg PA, Bianchi FB et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–38.PubMedCrossRefGoogle Scholar
  14. 14.
    Czaja AJ, Davis GL, Ludwig J, Taswell HP. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology. 1984;4:622–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology. 2002;36(Suppl. 1): S152–60.CrossRefGoogle Scholar
  17. 17.
    Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology. 1994;20:349–55.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114–25.PubMedCrossRefGoogle Scholar
  21. 21.
    Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–47.PubMedCrossRefGoogle Scholar
  22. 22.
    Scheuer P. Primary biliary cirrhosis. Proc R Soc Med. 1967;60:1257–60.PubMedGoogle Scholar
  23. 23.
    Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103–12.PubMedCrossRefGoogle Scholar
  24. 24.
    Locke GR 3rd, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996;23:52–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Van der Borght S, Libbrecht L, Katoonizadeh A et al. Nuclear beta-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology. 2007;51:855–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Bioulac-Sage P, Rebouissou S, Thomas C et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology. 2007;46:740–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Di Tommaso L, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725–34.PubMedCrossRefGoogle Scholar

Copyright information

© Springer and Falk Foundation e.V. 2008

Authors and Affiliations

  • C. Flechtenmacher
  • T. Longerich
  • P. Schirmacher
    • 1
  1. 1.Institute of PathologyUniversity HospitalHeidelbergGermany

Personalised recommendations